Virtus Fund Advisers’s Health Catalyst HCAT Stock Holding History

Virtus Fund Advisers’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,786	Closed	-$21K	–	124
2024 Q1	$21K	Buy	+2,786	New	+$25.4K	0.07%	105

Other funds holding HCAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Daventry Group New York $133M AUM 32.28% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Virtus Fund Advisers's HCAT Position: Q2 2024 in Review

Virtus Fund Advisers sold out of Health Catalyst (HCAT) in Q2 2024, closing a stake of 2,786 shares — an estimated $21K sold.

Virtus Fund Advisers first reported a position in HCAT in Q1 2024 and held it in 1 quarter. The position peaked at $21K in Q1 2024. 161 funds tracked by Wall St. Rank hold HCAT as of Q2 2024.

Virtus Fund Advisers reported no remaining Health Catalyst position as of Q2 2024 after selling out during the quarter.
Virtus Fund Advisers sold 2,786 Health Catalyst shares in Q2 2024, an estimated $21K.
Virtus Fund Advisers first reported a position in Health Catalyst in Q1 2024 and held it in 1 quarter.
Virtus Fund Advisers's Health Catalyst position peaked at $21K in Q1 2024.
161 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2024.

Based on Virtus Fund Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.